Syncom Formulations Holds 38th AGM on Sep 30, 2026, Declares 10% Dividend
Syncom Formulations (India) Limited held its 38th AGM on September 30, 2026. The company declared a 10% dividend (₹0.10 per share) for FY26. Key appointments confirmed included Rahul Vijay Bankda as MD and Rinki Ankit Bankda as Whole-Time Director. Remuneration for the CFO was also approved.
The declaration of a dividend and changes in key management positions can have a moderate impact on investor sentiment and the company's strategic direction.
The announcement reports the successful conclusion of the AGM, the declaration of a dividend, and several key board appointments and re-appointments, which are generally viewed positively by investors.
Syncom Formulations (India) Limited held its 38th Annual General Meeting (AGM) on Wednesday, September 30, 2026. The meeting commenced at 2:00 PM IST and concluded at 2:42 PM IST, conducted entirely through Video Conferencing (VC) or Other Audio Video Means (VC/OAVM).
The AGM proceedings included the adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026. A significant announcement was the declaration of a 10% dividend, amounting to ₹0.10 per equity share of face value ₹1, for the same financial year.
Key appointments and re-appointments were also confirmed during the meeting. Mr. Ankit Kedarmal Bankda was re-appointed as a director retiring by rotation. Mr. Rahul Vijay Bankda was confirmed as a Director and appointed as the Managing Director, with his remuneration approved. Similarly, Mrs. Rinki Ankit Bankda was confirmed as a Director and appointed as Whole-Time Director, with her remuneration approved. Mrs. Ruchi Jindal was re-appointed as a Woman Independent Director. Additionally, the remuneration of Mr. Ankur Vijay Bankda, Chief Financial Officer, was approved for an increase.
The meeting also ratified the remuneration of the Cost Auditor for the financial year 2026-27. The auditors' reports for both standalone and consolidated financial statements were presented and contained no qualifications or negative remarks. The Company Secretary informed that the results of the e-voting, conducted prior to and during the AGM, would be announced within two working days upon receipt of the Scrutinizer's Report.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.